GSK Investigational Site

Fort Collins, Colorado 80538

0 studies enrolling now · 27 studies all time

What they study most

Arthritis, Rheumatoid, Asthma, Bipolar Disorder, Epilepsy, HIV Infection, Infection, Human Immunodeficiency Virus I, Infections, Bacterial, Influenza, Human, Ischaemic Attack, Transient, Pulmonary Disease, Chronic Obstructive, Rhinitis, Allergic, Perennial, Rhinitis, Vasomotor

Studies at this site

• A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults — Completed
• Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) — Stopped early
• Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) — Stopped early
• A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease — Completed
• SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. — Completed
• Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies. — Completed
• Fosamprenavir Versus Other Protease Inhibitors — Completed
• Study Of Adults And Adolescents With Vasomotor Rhinitis — Completed
• An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B — Completed
• Safety Escalating Repeat IV, in Stroke Patients — Completed
• Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease — Completed
• Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults — Completed
• A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV — Completed
• Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations — Completed
• Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Lamotrigine Extended-Release In Elderly Patients With Epilepsy — Completed
• Study Of Allergic Rhinitis In Patients Who Also Have Asthma — Completed
• A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma — Completed
• A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD). — Completed
• Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease) — Completed
• ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies. — Stopped early
• Seasonal Allergic Rhinitis In Pediatric Subjects — Completed
• Bipolar Study in Adults at Least 18 Years of Age — Completed
• GSK BHR Study (Sont - Second Study) — Completed
• A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy — Completed